Delving into the Latest Updates on Roche Global Development with Synapse

Overview

Tags

Nervous System Diseases

Endocrinology and Metabolic Disease

Hemic and Lymphatic Diseases

Monoclonal antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Endocrinology and Metabolic Disease	1
Hemic and Lymphatic Diseases	1
Nervous System Diseases	1
Neoplasms	1

Top 5 Drug Type	Count

Monoclonal antibody	1

Top 5 Target	Count

TIGIT(T cell immunoglobulin and ITIM domains)	1

This study encompasses multicenter open-label, phase II trials.
Patients will be dispatched into 2 cohorts:
* Cohort A: Patients naïve from systemic treatment will be randomized according to two treatment modalities: atezolizumab + tiragolumab (arm A1) versus atezolizumab monotherapy (arm A2).
43 patients are to be included in each arm.
* Cohort B: Patients with previous exposure to ICI will be treated with the combination of atezolizumab and tiragolumab.
29 patients are to be included in this cohort.

Start Date01 Jan 2025

Sponsor / Collaborator

Institut Gustave Roussy EURL

[+1]

NCT00183898

/ Unknown statusPhase 2IIT

Phase II Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer

This study is for people with advanced gastric or gastroesophageal cancer. This study is being done to find out how long it takes tumors to grow after patients take the drugs capecitabine, oxaliplatin and cetuximab. Capecitabine (also called Xeloda) is a drug that has been approved by the Food and Drug Administration (FDA). Capecitabine has been approved for treatment of cancer of the colon and rectum. Oxaliplatin is another drug approved by the FDA. Oxaliplatin is also approved for treatment of cancer of the colon and rectum. Cetuximab is also a drug approved by the FDA for the treatment of cancer of the colon and rectum, as well as cancer of the head and neck. Capecitabine, oxaliplatin and cetuximab are not approved for gastric or gastroesophageal cancer. They are considered experimental drugs for this study. The purpose of this study is to see how long it takes patients' tumors to progress when they are taking oxaliplatin and capecitabine. Another purpose is to see how many tumors respond to this drug combination. The investigators also want to see how long people live when taking these drugs. The side effects of this drug combination will also be evaluated. This study will also measure the levels of certain genes (the cell's blueprint) in tumors. These genes affect how peoples' bodies react to the cancer drugs. Genes will also be measured in the blood. The investigators want to see how these genes can predict response to these study drugs.

Start Date28 Dec 2004

Sponsor / Collaborator

University of Southern California

[+3]

NCT00125021

/ CompletedPhase 2IIT

A Phase II Study of OSI-774 (Tarceva) in Combination With Capecitabine in Previously Treated Patients With Metastatic Pancreatic Cancer

This phase II trial is designed to investigate the effectiveness of Tarceva (OSI-774) combined with capecitabine in treating patients with metastatic pancreatic cancer.

Start Date01 Oct 2003

Sponsor / Collaborator

Dana-Farber Cancer Institute, Inc.

[+5]

100 Clinical Results associated with Roche Global Development

Login to view more data

0 Patents (Medical) associated with Roche Global Development

Login to view more data

3

Literatures (Medical) associated with Roche Global Development

Developing drugs on the fast track - building on chemistry in a regulatory career.

Author: Charpentier, B. A.

As time lines for drug discovery, testing and approval are compressed, the importance of planning and effective teamwork across scientific disciplines increases.The role of the regulatory professional at the interface of numerous scientific and legal disciplines also becomes more critical to successful drug development.Experience as a chemist can provide a strong science background and anal. thinking skills which are valuable tools in regulatory work.A knowledge of chem. is also directly applicable to addressing the regulatory aspects of many areas of drug development such as drug design, synthesis, formulation, manufacturing, quality testing, and measurement of drugs and metabolites in humans and animals.This presentation will breifly describe the role of chem. in regulatory and the role of regulatory in drug development, using the example of one chemist′s transition from the laboratory to regulatory.

Accelerating drug development - chemistry as a foundation for a regulatory career

Author: Charpentier, B. A.

As time lines for drug discovery, testing and approval are compressed, the importance of planning and effective teamwork across scientific disciplines increases.The role of the regulatory professional at the interface of numerous scientific and legal disciplines also becomes more critical to successful drug development.Experience as a chemist can provide a strong science background and anal. thinking skills which are valuable tools in regulatory work.A knowledge of chem. is also directly applicable to addressing the regulatory aspects of many areas of drug development such as drug design, synthesis, formulation, manufacturing, quality testing, and measurement of drugs and metabolites in humans and animals.This presentation will briefly describe the role of chem. in regulatory and the role of regulatory in drug development, using the example of one chemist′s transition from the laboratory to regulatory.

Chemistry as the foundation for a regulatory career in drug development.

Author: Charpentier, Bonnie A.

As time lines for drug discovery, testing and approval are compressed, the importance of planning and effective teamwork across scientific disciplines increases.The role of the regulatory professional at the interface of numerous scientific and legal disciplines also becomes more critical to successful drug development.Experience as a chemist can provide a strong science background and anal. thinking skills which are valuable tools in regulatory work.A knowledge of chem. is also directly applicable to addressing the regulatory aspects of many areas of drug development such as drug design, synthesis, formulation, manufacturing, quality testing, and measurement of drugs and metabolites in humans and animals.This presentation will briefly describe the role of chem. in regulatory and the role of regulatory in drug development, using the example of one chemist′s transition from the laboratory to regulatory.

100 Deals associated with Roche Global Development

Login to view more data

100 Translational Medicine associated with Roche Global Development

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 31 Mar 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2 Clinical

1

Login to view more data